CY1118441T1 - Παραγωγα 5-φθορο-ν-(πυριδιν-2-υλ)πυριδιν-2-αμινης που περιεχουν μια ομαδα σουλφοξιμινης - Google Patents
Παραγωγα 5-φθορο-ν-(πυριδιν-2-υλ)πυριδιν-2-αμινης που περιεχουν μια ομαδα σουλφοξιμινηςInfo
- Publication number
- CY1118441T1 CY1118441T1 CY20171100053T CY171100053T CY1118441T1 CY 1118441 T1 CY1118441 T1 CY 1118441T1 CY 20171100053 T CY20171100053 T CY 20171100053T CY 171100053 T CY171100053 T CY 171100053T CY 1118441 T1 CY1118441 T1 CY 1118441T1
- Authority
- CY
- Cyprus
- Prior art keywords
- pyridin
- fluoro
- products containing
- amine products
- group
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Cardiology (AREA)
- Hematology (AREA)
- Engineering & Computer Science (AREA)
- Virology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyridine Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Η παρούσα εφεύρεση σχετίζεται με παράγωγα 5-φθορο-Ν-(πυριδιν-2-υλ) πυριδιν-2-αμίνης που περιέχουν μία ομάδα σουλφοξιμίνης του γενικού τύπου (I) όπως περιγράφεται και ορίζεται εδώ, και μεθόδους για την παρασκευή τους, τη χρήση τους για την προφύλαξη από και/ή θεραπεία διαταραχών, ειδικότερα υπερπλαστικών διαταραχών και/ή προκαλούμενων από ιούς μολυσματικών νόσων και/ή καρδιαγγειακών νόσων. Η εφεύρεση σχετίζεται περαιτέρω με ενδιάμεσες ενώσεις χρήσιμες στην παρασκευή των εν λόγω ενώσεων του γενικού τύπου (I).
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP12192852 | 2012-11-15 | ||
PCT/EP2013/073637 WO2014076091A1 (en) | 2012-11-15 | 2013-11-12 | 5-fluoro-n-(pyridin-2-yl)pyridin-2-amine derivatives containing a sulfoximine group |
EP13792885.9A EP2928878B1 (en) | 2012-11-15 | 2013-11-12 | 5-fluoro-n-(pyridin-2-yl)pyridin-2-amine derivatives containing a sulfoximine group |
Publications (1)
Publication Number | Publication Date |
---|---|
CY1118441T1 true CY1118441T1 (el) | 2017-06-28 |
Family
ID=47148672
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CY20171100053T CY1118441T1 (el) | 2012-11-15 | 2017-01-17 | Παραγωγα 5-φθορο-ν-(πυριδιν-2-υλ)πυριδιν-2-αμινης που περιεχουν μια ομαδα σουλφοξιμινης |
Country Status (43)
Families Citing this family (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6858615B2 (en) | 2002-02-19 | 2005-02-22 | Parion Sciences, Inc. | Phenyl guanidine sodium channel blockers |
TWI555737B (zh) | 2011-05-24 | 2016-11-01 | 拜耳知識產權公司 | 含有硫醯亞胺基團之4-芳基-n-苯基-1,3,5-三氮雜苯-2-胺 |
AR086745A1 (es) | 2011-06-27 | 2014-01-22 | Parion Sciences Inc | 3,5-diamino-6-cloro-n-(n-(4-(4-(2-(hexil(2,3,4,5,6-pentahidroxihexil)amino)etoxi)fenil)butil)carbamimidoil)pirazina-2-carboxamida |
CA2888383A1 (en) | 2012-10-18 | 2014-04-24 | Bayer Pharma Aktiengesellschaft | N-(pyridin-2-yl)pyrimidin-4-amine derivatives containing a sulfone group |
CN104854091B (zh) | 2012-10-18 | 2018-04-03 | 拜耳药业股份公司 | 含砜基团的5‑氟‑n‑(吡啶‑2‑基)吡啶‑2‑胺衍生物 |
TW201418243A (zh) | 2012-11-15 | 2014-05-16 | Bayer Pharma AG | 含有磺醯亞胺基團之n-(吡啶-2-基)嘧啶-4-胺衍生物 |
JP6263193B2 (ja) | 2012-11-15 | 2018-01-17 | バイエル ファーマ アクチエンゲゼルシャフト | スルホキシイミン基を含んでいる5−フルオロ−n−(ピリジン−2−イル)ピリジン−2−アミン誘導体 |
KR20150095870A (ko) | 2012-12-17 | 2015-08-21 | 패리온 사이언스 인코퍼레이티드 | 3,5-디아미노-6-클로로-n-(n-(4-페닐부틸)카르밤이미도일)피라진-2-카르복스아미드 화합물 |
EP3150585A1 (en) | 2012-12-17 | 2017-04-05 | Parion Sciences, Inc. | Chloro-pyrazine carboxamide derivatives with epithelial sodium channel blocking activity |
CN105492438B (zh) | 2013-07-04 | 2018-08-07 | 拜耳医药股份有限公司 | 磺亚胺取代的5-氟-n-(吡啶-2-基)吡啶-2-胺衍生物以及其作为cdk9激酶抑制剂的用途 |
US9102633B2 (en) | 2013-12-13 | 2015-08-11 | Parion Sciences, Inc. | Arylalkyl- and aryloxyalkyl-substituted epithelial sodium channel blocking compounds |
US9856242B2 (en) | 2014-03-13 | 2018-01-02 | Bayer Pharma Aktiengesellscaft | 5-fluoro-N-(pyridin-2-yl)pyridin-2-amine derivatives containing a sulfone group |
WO2015150273A1 (en) | 2014-04-01 | 2015-10-08 | Bayer Pharma Aktiengesellschaft | Disubstituted 5-fluoro pyrimidine derivatives containing a sulfondiimine group |
TN2016000435A1 (en) | 2014-04-11 | 2018-04-04 | Bayer Pharma AG | Novel macrocyclic compounds. |
CA2964696C (en) | 2014-10-16 | 2022-09-06 | Bayer Pharma Aktiengesellschaft | Fluorinated benzofuranyl-pyrimidine derivatives containing a sulfoximine group |
CN107207475A (zh) | 2014-10-16 | 2017-09-26 | 拜耳医药股份有限公司 | 含有砜基团的氟化苯并呋喃基‑嘧啶衍生物 |
ES2786552T3 (es) | 2015-09-29 | 2020-10-13 | Bayer Pharma AG | Compuestos de sulfondiimina macrocíclicos nuevos |
CA3001085A1 (en) | 2015-10-08 | 2017-04-13 | Bayer Pharma Aktiengesellschaft | Novel modified macrocyclic compounds |
WO2017060322A2 (en) | 2015-10-10 | 2017-04-13 | Bayer Pharma Aktiengesellschaft | Ptefb-inhibitor-adc |
US11242356B2 (en) | 2017-03-28 | 2022-02-08 | Bayer Aktiengesellschaft | PTEFb inhibiting macrocyclic compounds |
WO2018177899A1 (en) | 2017-03-28 | 2018-10-04 | Bayer Aktiengesellschaft | Novel ptefb inhibiting macrocyclic compounds |
WO2019158517A1 (en) * | 2018-02-13 | 2019-08-22 | Bayer Aktiengesellschaft | Use of 5-fluoro-4-(4-fluoro-2-methoxyphenyl)-n-{4-[(s-methylsulfonimidoyl)methyl]pyridin-2-yl}pyridin-2-amine for treating diffuse large b-cell lymphoma |
EP4074699A4 (en) | 2019-12-09 | 2024-01-03 | Cspc Zhongqi Pharmaceutical Tech Shijiazhuang Co Ltd | COMPOUND USEFUL AS CYCLIN-DEPENDENT KINASE 9 INHIBITOR AND USE THEREOF |
JP2023517034A (ja) * | 2020-03-06 | 2023-04-21 | バイエル アクチェンゲゼルシャフト | Cdk12の阻害を介してがんに作用するイミダゾトリアジン |
CN116249701A (zh) * | 2020-10-12 | 2023-06-09 | 上海海雁医药科技有限公司 | 取代的二(吡啶-2-基)胺衍生物、其组合物及医药上的用途 |
CN117015539A (zh) * | 2022-03-25 | 2023-11-07 | 成都苑东生物制药股份有限公司 | 一种氨基吡啶类衍生物、其制备方法及用途 |
WO2024044757A1 (en) * | 2022-08-26 | 2024-02-29 | Sanford Burnham Prebys Medical Discovery Institute | Aminopyrimidine and aminotriazine derivatives as myc protein modulators |
WO2024097179A1 (en) * | 2022-11-02 | 2024-05-10 | Vincerx Pharma, Inc. | Combination therapies comprising a cdk9 inhibitor for cancer |
WO2024112656A1 (en) * | 2022-11-21 | 2024-05-30 | The Board Of Trustees Of The Leland Stanford Junior University | Use of a tyrosine kinase inhibitor for the treatment of hereditary hemorrhagic telangiectasia and pulmonary arterial hypertension |
Family Cites Families (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2556946T3 (es) | 2000-12-21 | 2016-01-21 | Novartis Ag | Pirimidinaminas como moduladores de la angiogénesis |
DE10239042A1 (de) | 2002-08-21 | 2004-03-04 | Schering Ag | Makrozyclische Pyrimidine, deren Herstellung und Verwendung als Arzneimittel |
DE10349423A1 (de) | 2003-10-16 | 2005-06-16 | Schering Ag | Sulfoximinsubstituierte Parimidine als CDK- und/oder VEGF-Inhibitoren, deren Herstellung und Verwendung als Arzneimittel |
WO2006064251A1 (en) | 2004-12-17 | 2006-06-22 | Astrazeneca Ab | 4- (4- (imidazol-4-yl) pyrimidin-2-ylamino) benzamides as cdk inhibitors |
DE102006041382A1 (de) * | 2006-08-29 | 2008-03-20 | Bayer Schering Pharma Ag | Carbamoyl-Sulfoximide als Proteinkinaseinhibitoren |
DE102006042143A1 (de) | 2006-09-08 | 2008-03-27 | Bayer Healthcare Aktiengesellschaft | Neue substituierte Bipyridin-Derivate und ihre Verwendung |
WO2008060248A1 (en) | 2006-11-15 | 2008-05-22 | S*Bio Pte Ltd. | Indole sustituted pyrimidines and use thereof in the treatment of cancer |
WO2008079918A1 (en) | 2006-12-22 | 2008-07-03 | Novartis Ag | Indol-4-yl-pyrimidinyl-2-yl-amine derivatives and use thereof as cyclin dependant kinase inhibitors |
MX2009006536A (es) | 2006-12-22 | 2009-06-26 | Novartis Ag | Compuestos de heteroaril-heteroarilo como inhibidores de cdk para el tratamiento de cancer, inflamacion e infecciones virales. |
EP2137166B1 (en) * | 2007-04-24 | 2012-05-30 | Ingenium Pharmaceuticals GmbH | 4, 6-disubstituted aminopyrimidine derivatives as inhibitors of protein kinases |
WO2008129071A1 (en) | 2007-04-24 | 2008-10-30 | Ingenium Pharmaceuticals Gmbh | Inhibitors of protein kinases |
US8436007B2 (en) | 2007-04-24 | 2013-05-07 | Ingenium Pharmaceuticals Gmbh | Inhibitors of protein kinases |
WO2008132138A1 (en) | 2007-04-25 | 2008-11-06 | Ingenium Pharmaceuticals Gmbh | Derivatives of 4,6-disubstituted aminopyrimidines |
WO2009029998A1 (en) | 2007-09-06 | 2009-03-12 | Cytopia Research Pty Ltd | Retrometabolic compounds |
GB0805477D0 (en) | 2008-03-26 | 2008-04-30 | Univ Nottingham | Pyrimidines triazines and their use as pharmaceutical agents |
US8415381B2 (en) | 2009-07-30 | 2013-04-09 | Novartis Ag | Heteroaryl compounds and their uses |
JP5921525B2 (ja) | 2010-03-22 | 2016-05-24 | リード ディスカバリー センター ゲゼルシャフト ミット ベシュレンクテル ハフツング | 医薬的に活性のある二置換のトリアジン誘導体 |
WO2012101063A1 (en) * | 2011-01-28 | 2012-08-02 | Novartis Ag | N-acyl pyridine biaryl compounds and their uses |
ES2567066T3 (es) * | 2011-03-02 | 2016-04-19 | Lead Discovery Center Gmbh | Derivados de piridina disustituida farmacéuticamente activos |
EP2527332A1 (en) * | 2011-05-24 | 2012-11-28 | Bayer Intellectual Property GmbH | 4-Aryl-N-phenyl-1,3,5-triazin-2-amines containing a sulfoximine group as CDK9 inhibitors |
CN103917527B (zh) | 2011-09-16 | 2017-05-31 | 拜耳知识产权有限责任公司 | 二取代的5‑氟‑嘧啶 |
ES2588102T3 (es) | 2011-09-16 | 2016-10-28 | Bayer Intellectual Property Gmbh | Derivados de 5-fluoro-pirimidina disustituidos que contienen un grupo sulfoximina |
CN104854091B (zh) * | 2012-10-18 | 2018-04-03 | 拜耳药业股份公司 | 含砜基团的5‑氟‑n‑(吡啶‑2‑基)吡啶‑2‑胺衍生物 |
CA2888381A1 (en) | 2012-10-18 | 2014-04-24 | Bayer Pharma Aktiengesellschaft | 4-(ortho)-fluorophenyl-5-fluoropyrimidin-2-yl amines containing a sulfone group |
EP2920153B1 (en) | 2012-11-15 | 2017-02-01 | Bayer Pharma Aktiengesellschaft | 4-(ortho)-fluorophenyl-5-fluoropyrimidin-2-yl amines containing a sulfoximine group |
JP6263193B2 (ja) | 2012-11-15 | 2018-01-17 | バイエル ファーマ アクチエンゲゼルシャフト | スルホキシイミン基を含んでいる5−フルオロ−n−(ピリジン−2−イル)ピリジン−2−アミン誘導体 |
CN105492438B (zh) | 2013-07-04 | 2018-08-07 | 拜耳医药股份有限公司 | 磺亚胺取代的5-氟-n-(吡啶-2-基)吡啶-2-胺衍生物以及其作为cdk9激酶抑制剂的用途 |
US9856242B2 (en) | 2014-03-13 | 2018-01-02 | Bayer Pharma Aktiengesellscaft | 5-fluoro-N-(pyridin-2-yl)pyridin-2-amine derivatives containing a sulfone group |
-
2013
- 2013-11-12 JP JP2015542247A patent/JP6263193B2/ja active Active
- 2013-11-12 NZ NZ70708413A patent/NZ707084A/en unknown
- 2013-11-12 HU HUE13792885A patent/HUE032868T2/en unknown
- 2013-11-12 KR KR1020157015423A patent/KR102242871B1/ko active IP Right Grant
- 2013-11-12 EA EA201590890A patent/EA027226B1/ru not_active IP Right Cessation
- 2013-11-12 MA MA38090A patent/MA38090B1/fr unknown
- 2013-11-12 UA UAA201505911A patent/UA115254C2/uk unknown
- 2013-11-12 PT PT137928859T patent/PT2928878T/pt unknown
- 2013-11-12 PL PL13792885T patent/PL2928878T3/pl unknown
- 2013-11-12 WO PCT/EP2013/073637 patent/WO2014076091A1/en active Application Filing
- 2013-11-12 EP EP13792885.9A patent/EP2928878B1/en active Active
- 2013-11-12 LT LTEP13792885.9T patent/LT2928878T/lt unknown
- 2013-11-12 ME MEP-2017-16A patent/ME02880B/me unknown
- 2013-11-12 CN CN201380070440.8A patent/CN105102444B/zh active Active
- 2013-11-12 RS RS20170009A patent/RS55580B1/sr unknown
- 2013-11-12 AU AU2013346939A patent/AU2013346939B2/en active Active
- 2013-11-12 AP AP2015008432A patent/AP3872A/en active
- 2013-11-12 DK DK13792885.9T patent/DK2928878T3/en active
- 2013-11-12 ES ES13792885.9T patent/ES2612978T3/es active Active
- 2013-11-12 MY MYPI2015701520A patent/MY170609A/en unknown
- 2013-11-12 SG SG11201503079PA patent/SG11201503079PA/en unknown
- 2013-11-12 PE PE2015000630A patent/PE20151071A1/es active IP Right Grant
- 2013-11-12 CA CA2891358A patent/CA2891358C/en active Active
- 2013-11-12 SI SI201330389A patent/SI2928878T1/sl unknown
- 2013-11-12 US US14/443,279 patent/US9650340B2/en active Active
- 2013-11-12 MX MX2015006169A patent/MX2015006169A/es active IP Right Grant
- 2013-11-12 BR BR112015010707-9A patent/BR112015010707B1/pt active IP Right Grant
- 2013-11-13 JO JOP/2013/0330A patent/JO3332B1/ar active
- 2013-11-15 UY UY0001035141A patent/UY35141A/es not_active Application Discontinuation
- 2013-11-15 AR ARP130104211A patent/AR093505A1/es active IP Right Grant
- 2013-11-15 TW TW102141761A patent/TWI613193B/zh active
-
2015
- 2015-04-16 IL IL238322A patent/IL238322A/en active IP Right Grant
- 2015-05-05 PH PH12015501003A patent/PH12015501003B1/en unknown
- 2015-05-14 TN TNP2015000185A patent/TN2015000185A1/fr unknown
- 2015-05-14 CL CL2015001304A patent/CL2015001304A1/es unknown
- 2015-05-15 CR CR20150256A patent/CR20150256A/es unknown
- 2015-05-15 DO DO2015000118A patent/DOP2015000118A/es unknown
- 2015-05-15 CU CU2015000052A patent/CU20150052A7/es unknown
- 2015-05-15 SV SV2015004979A patent/SV2015004979A/es unknown
- 2015-05-15 EC ECIEPI201519323A patent/ECSP15019323A/es unknown
-
2016
- 2016-02-02 HK HK16101158.8A patent/HK1213255A1/zh unknown
- 2016-11-22 HR HRP20161547TT patent/HRP20161547T1/hr unknown
-
2017
- 2017-01-17 CY CY20171100053T patent/CY1118441T1/el unknown
- 2017-04-03 US US15/477,974 patent/US9877954B2/en active Active
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CY1118441T1 (el) | Παραγωγα 5-φθορο-ν-(πυριδιν-2-υλ)πυριδιν-2-αμινης που περιεχουν μια ομαδα σουλφοξιμινης | |
CY1116791T1 (el) | 4-αρυλ-ν-φαινυλ-1,3,5-τριαζιν-αμινες που περιεχουν μια ομαδα σουλφοξιμινης | |
CY1120673T1 (el) | 2-(μορφολιν-4-υλ)-1,7-ναφθυριδινες | |
CY1120969T1 (el) | Παραγωγα κινοξαλινης χρησιμα ως τροποποιητες fgfr κινασης | |
CY1119143T1 (el) | Διεργασια για την παρασκευη παραγωγων και ενδιαμεσων καρβαμουλοπυριδονης | |
CA2917096C (en) | Sulfoximine substituted 5-fluoro-n-(pyridin-2-yl)pyridin-2-amine derivatives and their use as cdk9 kinase inhibitors | |
CY1116775T1 (el) | Παραγωγα πυριμιδονης ως αναστολεις της ιστικης τρανσγλουταμινασης | |
UA116648C2 (uk) | Фумарати як проліки та їх застосування при лікуванні різних захворювань | |
CY1115945T1 (el) | Παραγωγα πυραζολοκινολινονης, η παρασκευη τους και η θεραπευτικη τους χρηση | |
WO2014060375A3 (en) | 5-fluoro-n-(pyridin-2-yl)pyridin-2-amine derivatives containing a sulfone group | |
CY1117123T1 (el) | Παραγωγα οιστρα-1,3,5(10),16-τετραενο-3- καρβοξαμιδιου, μεθοδοι για την παραγωγη αυτων, φαρμακευτικα παρασκευασματα που τα περιεχουν καθως και η χρηση αυτων για την παραγωγη φαρμακευτικων μεσων | |
TN2015000186A1 (en) | N-(pyridin-2-yl)pyrimidin-4-amine derivatives containing a sulfoximine group | |
PH12016501968A1 (en) | Novel macrocyclic compounds | |
CY1119108T1 (el) | Τηγμενα πυρρολοδικαρβοξαμιδια και η χρηση τους ως φαρμακευτικα προϊοντα | |
MX2013012233A (es) | 4-aril-n-fenil-1,3,5-triazin-2-aminas sustituidas. | |
CY1118399T1 (el) | Ενωσεις βενζοφουρανιου για την θεραπεια μολυνσεων ιου ηπατιτιδας c | |
EA201591406A1 (ru) | C-19 модифицированные тритерпеноиды с ингибиторной активностью созревания вич | |
CY1120185T1 (el) | Υποκατεστημενα πυριδινικα παραγωγα χρησιμα ως αναστολεις c-fms κινασης | |
CY1117416T1 (el) | Παραγωγα βενζαζολης ως προσδετες του υποδοχεα ισταμινης η4 | |
UY36938A (es) | Nuevos compuestos macrocíclicos modificados | |
WO2014060493A3 (en) | N-(pyridin-2-yl)pyrimidin-4-amine derivatives containing a sulfone group | |
CY1117210T1 (el) | Παραγωγα 2-οξο-1-ιμιδαζολιδινυλ ιμιδαζοθειαδιαζολης | |
CY1122381T1 (el) | Παραγωγα ιμιδαζοπυριδαζινης ως αναστολεις pi3kbhta | |
CY1118852T1 (el) | Παραγωγα πυριμιδοοξαζοσινης ως αναστολεις της mtor | |
CY1119666T1 (el) | Φαρμακευτικες συνθεσεις |